Full-Time

Patent Attorney

Confirmed live in the last 24 hours

Scribe Therapeutics

Scribe Therapeutics

51-200 employees

Develops CRISPR-based genetic medicine solutions

Biotechnology
Healthcare

Compensation Overview

$180k - $240kAnnually

+ Incentives

Mid

Alameda, CA, USA

Must have a JD degree and be admitted to practice in California.

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • JD degree and admitted to practice in the state of California
  • MS, or doctorate in molecular biology; specialization in CRISPR technology preferred
  • 3-5 years in law firm experience
  • Demonstrated experience in patent and claim drafting
  • Ability to interpret and present research data and other complex information
  • Exceptional oral and written communication skills
  • Strong organizational abilities and experience in a multitasking environment; ability to prioritize and meet deadlines
  • Good interpersonal skills
  • Ability to communicate scientific information in a clear and concise manner
  • Proficiency in Microsoft Office or equivalent products, including manipulation of graphs and figures
  • Ability to work collaboratively in a fast-paced, interdisciplinary research team
Responsibilities
  • Draft patent specifications and claims
  • Draft responses to patent office actions
  • Interact with senior in-house patent attorney and outside counsel for patent drafting, prosecution, and strategy
  • Assist in the oversight of the patent portfolio
  • Review scientific and patent literature to monitor competitive landscape
  • Perform patent key word and assignee searches to monitor competitive landscape and FTO analyses; communicate findings to project teams
  • Effectively collaborate with members within a fully-integrated team to facilitate execution on projects within established timelines for generation of reports and on-time integration into patent applications, as well as
  • Independently work with R&D staff to provide recommendations on experimental design and experiments to be performed to support patent applications

Scribe Therapeutics focuses on genetic medicine by utilizing CRISPR technology to develop solutions for genetic diseases. CRISPR acts like molecular scissors, allowing for precise editing of DNA sequences to potentially correct genetic defects. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies, generating revenue through partnerships and licensing its technology. Scribe Therapeutics is also working on advanced delivery methods for in vivo applications, enabling targeted gene therapy that can address specific genetic variants. Unlike many competitors, Scribe emphasizes exceptional specificity in its gene-editing approach, aiming to provide precise treatments for genetic disorders. The ultimate goal is to advance the field of genetic medicine and improve patient outcomes through effective gene therapies.

Company Stage

N/A

Total Funding

$136.2M

Headquarters

Alameda, California

Founded

2017

Growth & Insights
Headcount

6 month growth

11%

1 year growth

17%

2 year growth

81%
Simplify Jobs

Simplify's Take

What believers are saying

  • Scribe's innovative XE and ELXR platforms have demonstrated high efficacy and safety in non-human primate studies, indicating strong potential for human applications.
  • The company's partnerships with industry giants like Sanofi and Eli Lilly provide significant financial backing and collaborative opportunities, enhancing its growth prospects.
  • Scribe's recent appointments of experienced leaders in R&D and discovery biology strengthen its scientific and operational capabilities.

What critics are saying

  • The highly competitive genetic medicine market requires continuous innovation to maintain a leading position.
  • Dependence on partnerships for revenue generation could pose risks if collaborations do not yield expected outcomes.

What makes Scribe Therapeutics unique

  • Scribe Therapeutics leverages its proprietary CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies, which offer superior potency and specificity compared to traditional CRISPR-Cas9 systems.
  • The company's focus on in vivo genetic medicine and allele-specific targeting sets it apart in the genetic medicine market, enabling precise therapeutic interventions.
  • Scribe's strategic partnerships with major pharmaceutical companies like Sanofi and Eli Lilly's Prevail Therapeutics highlight its credibility and potential for large-scale impact.

Help us improve and share your feedback! Did you find this helpful?